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ABSTRACT 
PENICILLIN USE AND DURATION OF BACTEREMIA, LENGTH OF STAY, 
AND 30-DAY READMISSION IN HOSPITALIZED PATIENTS WITH 
PENICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS 
 
MAY 2014 
PHINNARA J. HAS, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Susan E. Hankinson 
 
Staphylococcus aureus is the most common bacterial pathogen in hospitalized patients, 
and is a leading cause of bacteremia.  Current guidelines recommend when the etiology 
of infection is known or suspected, the antimicrobial most cost-effective, least toxic, and 
most narrow in spectrum be used.  To evaluate treatment of PSSA bacteremia with 
penicillin versus other antibiotics, a retrospective cohort study was conducted at a tertiary 
care center in Western Massachusetts using data collected from 2003 to 2013.  One-
hundred and eight patients with PSSA bacteremia were included.  The primary exposure 
was defined as treatment with penicillin within 3 days of the first positive culture.  The 
primary outcome was duration of bacteremia, with length of hospital stay and 30-day 
readmission as secondary outcomes.  Data were abstracted from administrative databases 
and medical records, and multivariable and propensity-score-adjusted analyses were 
conducted.  Overall, there was no difference in duration of bacteremia according to 
treatment (p=0.77), and a non-significant 25% increase in length of stay post-culture was 
observed in patients not receiving penicillin (p=0.34).  Propensity-score-adjusted 
analyses also did not yield significant differences in clinical outcomes.  The results of this 
 vii 
 
study suggest no significant associations between treatment with penicillin versus other 
antibiotics and clinical outcomes.  Given the low cost and decreased risk of developing 
multidrug-resistant bacteria, PSSA bacteremia should be treated preferentially with 
penicillin.  However, given the small sample size, and the potentially wide range of 
antibiotics used in place of penicillin, caution should be exercised in interpreting these 
results.  Larger multi-site studies are needed to address these associations. 
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CHAPTER 1 
INTRODUCTION 
 
Staphylococcus aureus is a common cause of infection, particularly in healthcare 
settings, and is a leading cause of bacteremia.  The prevalence of both community-
acquired and nosocomial infections has been steadily increasing over the past two 
decades.
1,4
 Although more commonly associated with skin and soft tissue infections, S. 
aureus has been observed to be the most common cause of nosocomial pneumonia and 
surgical site infections,
1
 and is also the most common bacterial pathogen among clinical 
isolates in hospitalized patients.
22
 In 2006, Kuehnert et al. conducted a study among 9622 
individuals who were part of the National Health and Nutrition Examination Survey 
(NHANES).
3
 The authors observed that about one-third of the United States population 
had S. aureus colonization, although carriage rates can be as high as 50% among high-
risk populations, such as injection drug-users, insulin-dependent diabetics, and patients 
with intravascular catheters.
2
  
 The first strains of S. aureus to be resistant to penicillin were observed in the 
1940’s, shortly after penicillin was introduced.2 Initially, these strains were rare, 
however, as the use of penicillin became more widespread, the prevalence of penicillin-
resistant strains began to increase.  It was first observed in Denmark that by 1966, 85% - 
90% of hospital isolates were resistant to penicillin.  Resistant strains are also common in 
the community.  In the US, by the 1970’s, 70% - 85% of community isolates were 
resistant to penicillin.
2
 A review article by Lowy in 1998 described that less than 5% of 
isolates remained susceptible to penicillin.
4
 2 
 
 The development of antibiotic resistance has been ushered in by two key factors; 
overuse and misuse of antibiotics.  Frequently, antibiotics are prescribed for an indication 
that is not warranted, or is not ideal.
6
 It has been reported that a large proportion (~75%) 
of ambulatory antibiotic prescriptions are for conditions such as otitis media, sinusitis, 
bronchitis, and upper respiratory infections.  Antibiotic therapy is frequently unnecessary, 
because the etiologies of these conditions are predominantly viral.
21
  
Appropriate antibiotic therapy is generally defined as treatment with an agent to 
which the causative pathogen is susceptible in vitro.  Inappropriate therapy has been 
associated with poor clinical outcomes, such as increased risk of mortality or increased 
length of hospital stay.
7,8
 The Infectious Diseases Society of America (IDSA) guidelines 
recommend that when an etiologic diagnosis is known or suspected, the antimicrobial 
agent that is the most cost-effective, least toxic, and most narrow in spectrum be used.
9
   
 Recent evidence has suggested that there is a resurgence of penicillin-susceptible 
S. aureus (PSSA).
11-13
  The reason for this increase of PSSA is unclear; however, Crane 
posits that a focus on more resistant strains, such as methicillin-resistant S. aureus 
(MRSA), has created an opportunity for penicillin-susceptible strains to resurface.
12
 In 
2013, Nissen et al, describes that PSSA accounted for one-fifth of cases of SAB in 
Denmark.
11
 In an editorial response to this study, Crane observed a similar resurgence of 
PSSA at 417-bed hospital in Buffalo, New York.  PSSA accounted for 13 to 15% of all 
cases of S. aureus among patients.  Similarly, according to the 2012 antibiogram at 
Baystate Medical Center in Springfield, Massachusetts, approximately 20% of all 
methicillin-susceptible S. aureus tested were also susceptible to penicillin.
13
 Based on 
data indicating superior potency of penicillin over other penicillinase-resistant β-lactams, 
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it is recommended that penicillin should be considered as the drug of choice for treating 
PSSA.
11
 
 A common consequence of S. aureus infection is S. aureus bacteremia (SAB).  
SAB can be a serious condition with high mortality rates ranging from 11 to 43%.
4,10
 
Bacteremia is defined as presence of S. aureus in the bloodstream as confirmed by a 
positive blood culture result.  Factors associated with mortality in SAB include age over 
50 years, inadequate source control of infection, and serious underlying cardiac, 
neurologic, or respiratory disease.
4 
There is a paucity of literature investigating PSSA, and the associations between 
treatment with penicillin versus other antibiotics and clinical outcomes.  There has only 
been one study to date where this was the focus, although only the endpoint of 30-day 
mortality was evaluated.
11
 Three studies have considered duration of bacteremia as an 
outcome
14,15,24
; however, these studies were evaluating other therapies versus standard 
care in methicillin-resistant and susceptible S. aureus isolates
24
, or where the 
susceptibilities were not specified
14,15
.  One of these studies was conducted over 30 years 
ago.
15 
To date, there have been no studies that investigated the association of penicillin 
treatment with readmission as an outcome.   
Therefore, we proposed to conduct a retrospective cohort study comparing the 
effectiveness of treatment with penicillin versus other antibiotics among patients 
hospitalized with PSSA at Baystate Medical Center in Springfield, Massachusetts.  We 
hypothesized that among hospitalized patients with PSSA bacteremia, after adjusting for 
patient characteristics, those whose antibiotics were appropriately switched to penicillin 
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will have a shorter duration of bacteremia, shorter length of stay, and lower rates of 30-
day readmission as compared to patients who were treated with other antibiotics. 
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CHAPTER 2 
METHODS 
2.1   Study Population 
Baystate Medical Center in Springfield, Massachusetts is a tertiary care facility 
serving an ethnically and socioeconomically diverse population.  Patients aged 18 years 
or older who were admitted between January 2003 and January 2013 with a confirmed 
diagnosis of PSSA bacteremia were included in this study.  PSSA bacteremia was defined 
as at least one positive blood culture for S. aureus that was susceptible to penicillin.  The 
initial study sample consisted of 6455 S. aureus cultures drawn at Baystate between 2003 
and 2013.   
Of the original sample of 6455 cultures, exclusion criteria consisted of duplicate 
cultures (n=1250), coagulase-negative Staphylococci (n=2319), and penicillin-resistant S. 
aureus (n=2545).  Additionally, to ensure the same patient was not included more than 
once in the study, repeat cultures drawn within six weeks of the index culture (n=166) 
were excluded.  Patients were also excluded if a subsequent negative culture was not 
available (n=22), and if there was documentation of a penicillin allergy (n=16).  Patients 
under 18 years of age were also excluded (n=29).  This left a sample size of 108 unique 
patients for analysis.  Additional exclusion criteria were necessary for the analysis of 
each outcome.  Analyses for duration of bacteremia excluded patients whose duration 
was less than 3 days.  For total and LOS post-culture analyses, patients with an LOS post-
culture of less than 3 days were excluded.  Also, analyses for 30-day readmission 
required that 10 deaths, as well as patients with LOS post-culture less than 3 days be 
excluded (Figure 1). 
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2.2 Data Collection 
Data for our study were abstracted from MedMined and McKesson databases, as 
well as electronic medical records.  MedMined Data Mining Surveillance program 
(CareFusion Corporation, San Diego, CA) was designed to identify clinically meaningful 
patterns in data sets, relying on microbiologic and patient location data.
16
 McKesson is a 
large administrative database maintained for billing purposes.  Using MedMined, 
microbiological data such as S. aureus drug sensitivities and results of blood cultures 
were extracted.  Demographic and other clinical data were abstracted from McKesson 
and electronic medical records.   Data from these three sources were then merged to 
construct a de-identified data set for our study which is in compliance with established 
Health Insurance Portability and Accountability Act (HIPAA) regulations.   
The primary exposure was treatment with penicillin, and was assessed through 
McKesson, a database maintained for billing purposes.  All antibiotics a patient would 
have received during their admission are reflected in this database.  We defined treatment 
with penicillin as having received penicillin within 3 days of the first positive blood 
culture.  Patients receiving another antibiotic, or receiving penicillin more than 3 days 
after the first positive culture were defined as receiving no or late penicillin.  Treatment 
groups were defined this way because patients’ antibiotics would not have been switched 
to penicillin until approximately 48 hours after the initial blood culture is drawn, as this is 
the time required for susceptibility tests to be completed.  Defining treatment with 
penicillin as within 3 days of the culture not only captures if a patient was treated with 
penicillin, but if the timing of treatment was appropriate; in other words, within 24 hours 
of the when results were available to clinicians. 
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The primary outcome of interest was duration of bacteremia, which was defined as 
the time interval from the first positive blood culture to the first negative culture.  Results 
and dates of the first positive culture were extracted from MedMined, while results and 
dates of the first negative blood culture were abstracted from medical records.  Duration 
of bacteremia was then calculated as the difference between these dates, in days.  
Secondary outcomes included length of stay (LOS) in days, and all-cause 30-day 
readmission, which were available through McKesson.  Length of stay was further 
divided into total LOS, LOS before the positive culture, and LOS post-culture.   
Covariates were selected based on inclusion in prior literature and potential for 
confounding.  Data on covariates were assessed through McKesson, or abstraction from 
electronic medical records.  The following covariates were assessed via McKesson: age, 
sex, race, Charlson Comorbidity Index (CCI), transfer to ICU during hospitalization, 
admission in previous 90 days, admission source, discharge disposition, and community 
acquired infection.  The CCI was defined as two levels of comorbidity categories: 
low/intermediate (CCI score = 0-2), and high (CCI score ≥3), and was calculated from 
secondary diagnoses compiled from McKesson using the International Classification of 
Diseases, 9
th
 revision (ICD-9).  Admission source was categorized as home, transfer from 
skilled nursing facility (SNF), emergency department, MD/referral, and other.  Discharge 
disposition was categorized as long-term care, death, home, acute/short-term care, and 
other.  Community acquired infection was defined as LOS before positive culture ≤3 
days.  
Covariates that were abstracted from electronic medical records included: diabetes 
mellitus, malignancy, current chemotherapy, requirement for dialysis, illicit injection 
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drug use, presence of a surgical wound, presence of an indwelling catheter, site of 
infection, and infectious disease consult.  Site of infection was categorized as catheter 
related, respiratory, endocarditis, osteomyelitis, dialysis access, other, and unknown. 
 
2.3   Statistical Analysis 
The distribution of all variables was examined.  Demographic data and other 
categorical variables were reported as frequencies and percentages.  Continuous variables 
were reported with means and standard deviations, medians, range and quartiles.  
Distribution of duration of bacteremia by covariates was examined, and significance 
testing was performed using Spearman’s rank correlation for continuous and ordinal 
variables, and ANOVA for categorical variables.  Length of stay is right skewed; 
therefore, bivariate distributions of total LOS and LOS post-culture by covariates were 
analyzed using non-parametric tests.  Significance testing for continuous and ordinal 
variables was performed using Spearman’s rank correlation, and Kruskal-Wallis was 
used for categorical variables.  Bivariate distribution of 30-day readmission by covariates 
was also examined.  Significance testing was performed using independent t-tests for 
continuous variables, Wilcoxon’s rank-sum for ordinal variables, and Fisher’s exact test 
for categorical variables.  Ten deaths were excluded in all analyses of 30-day 
readmission, as well as patients whose LOS post-culture was less than 3 days, leaving 69 
individuals available for analysis. 
For the primary outcome of duration of bacteremia, a multiple linear regression 
model was used to estimate beta coefficients, and adjust for patient characteristics as 
potential confounders.  For consistency with LOS analyses, duration of bacteremia was 
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log-transformed prior to fitting the linear regression model.  Covariates selected for this 
model included sex, current chemotherapy, and where the patient was admitted from.  To 
select for covariates, variables with a p-value of ≤0.25 from the bivariate analysis of 
duration of bacteremia were included in the initial model.  After running the initial 
model, variables with a Wald p-value >0.10 were evaluated individually by removing that 
variable from the model.  If the coefficient for treatment with penicillin changed by 
>15%, the variable was retained in the model.  Treatment with penicillin was defined as 
receiving penicillin within 3 days of the positive culture; therefore, it was necessary to 
exclude patients if their bacteremia resolved during those 3 days.  This left a sample size 
of 79 for the multivariable analysis of duration of bacteremia. 
Linear regression models were also used to estimate beta coefficients for total LOS 
and LOS post-culture.  Because LOS is right skewed, data were log-transformed prior to 
fitting the multivariable models.  Covariates selected for the total LOS model included 
race, transfer to ICU during admission, community acquired infection, and admission 
source.  Covariates selected for the LOS after culture model included age, injection drug 
use, transfer to ICU during hospitalization, community acquired infection, previous 
admission within 90 days, admission source, and infectious disease consult.  Covariates 
were selected in the same manner as previously described for duration of bacteremia.  As 
with the duration of bacteremia model, patients with an LOS post-culture of less than 3 
days were excluded from the analysis in order to avoid including patients who were 
discharged before treatment with penicillin was begun.  This exclusion left a sample size 
of 75 for the LOS post-culture and total LOS multivariable analyses. 
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 Survival functions for each group were also compared using Kaplan-Meier 
estimates for total LOS and LOS post-culture.  Survival functions that diverge early and 
meet late are indicative of inherent differences between the two groups that may not be 
observed when comparing means or medians.  Kaplan-Meier plots were constructed to 
verify findings observed from comparison of means and medians. 
Logistic regression was used to estimate odds ratios and adjust for patient 
characteristics for the multivariable analysis of 30-day readmission.  As previously noted, 
10 deaths were excluded, leaving a sample size of 98 individuals for the analysis.  The 
logistic regression model for 30-day readmission was adjusted for admission within 
previous 90 days.  Variables with a p-value of ≤0.25 from the bivariate analysis of 
duration of bacteremia were included in the initial model.  Starting with variables with 
the highest p-values from the Wald test, a formal log-likelihood ratio test was conducted 
to determine inclusion of variables in the final model.  Those with log-likelihood ratio 
test p-values <0.05 were included in the final model, or if removal of a variable resulted 
in a >15% change in the coefficient for treatment with penicillin.   
To address the concern of confounding by indication, we estimated a propensity 
score from logistic regression models.  The propensity model to estimate the probability 
that a patient will receive treatment with penicillin was developed based on a non-
parsimonious multivariable logistic regression model using variables previously 
described in the covariate assessment section.  Variables included in estimation of the 
propensity score were previous admission within the past 90 days, year of admission, 
ICU transfer, sex, race, age, illicit injection drug use, surgical wound, indwelling 
catheter, dialysis requirement, infectious disease consult, diabetes mellitus, and the 
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Charlson Comorbidity Index.  Of these, variables marginally associated with treatment at 
a p-value ≤ 0.25 were injection drug use, indwelling catheter, dialysis requirement, and 
diabetes.  However, to consider as many patient characteristics as possible in the 
propensity score, all variables were retained in the model.   
In order to assess fitness of our propensity score model, we conducted a Hosmer-
Lemeshow goodness of fit test.  The results of this test yielded a p-value of 0.25, 
indicating that this model adequately fits our data.  The area under the receiver operating 
characteristic (ROC) curve was also analyzed to determine if this model exhibited 
acceptable discrimination between treatment groups.  The area under the ROC was 0.80 
(95% CI, 0.68 – 0.92), indicating acceptable discrimination; in other words, 80% of the 
time, this model will correctly discriminate between patients who received penicillin and 
those who did not, or received penicillin late.  The fitness of the propensity score model 
indicates that the estimated propensity score should adequately address potential 
confounding by indication.  Therefore, in separate analyses to account for patient 
characteristics that may influence whether or not a patient is treated with penicillin, the 
propensity score was used as a covariate in a multivariable model.   
Sensitivity analyses were conducted by redefining the primary exposure variable as 
receiving penicillin within 4 days of the positive culture, or receiving another antibiotic 
or penicillin after 4 days of the culture.  Similar to our primary analyses, patients with 
outcomes occurring prior to 4 days post-culture were excluded from the analyses.  
Multivariable analyses for all outcomes were then repeated. 
 Two-sided p-values <0.05 were considered statistically significant. All analyses 
were performed using Stata 13.1 (College Station, Tx). 
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CHAPTER 3 
RESULTS 
 
 After initial exclusion criteria, 108 unique patients were available for analysis.   
The average age of the population was 64 years, and the majority were male (69%) and 
white (81%).   There were 16 patients who received penicillin within 3 days, and 92 who 
either received another antibiotic or received penicillin after 3 days.  Table 1 depicts 
baseline characteristics of the study population by treatment group.  Fifteen percent of the 
study population received penicillin within an appropriate time frame, and 85% did not 
receive penicillin or received penicillin more than 3 days post-culture.  Variables at least 
marginally associated with treatment (p ≤ 0.25) included diabetes mellitus, injection drug 
use, transfer to ICU during hospitalization, site of infection, infectious disease consult, 
and discharge disposition. 
 Tables 2 and 3 describe the distribution of outcomes for the study population.  
After exclusion of patients with duration of bacteremia less than 3 days, 79 patients were 
left for analysis.  The mean duration was 4.6 days and ranged from 3 to 9 days.  After 
excluding patients with an LOS post-culture less than 3 days, 75 patients were available 
for all LOS analyses.  Median total length of stay was 14 days, and ranged from 4 to 71 
days.  Length of stay after the positive culture had a median of 9 days, and a range from 3 
to 49 days.  LOS outcomes are characteristically right skewed, as illustrated in Figures 3 
and 5.  After excluding 10 deaths and patients with LOS post-culture less than 3 days, 15 
patients (22%) were readmitted within 30-days, and 54 (78%) were not. 
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 Tables 4, 5 and 6 show the distribution of outcomes by covariates for the study 
population.  For duration of bacteremia, variables that were at least marginally associated 
(p ≤ 0.25) were age, diabetes mellitus, and current chemotherapy (Table 4).  Variables 
associated with LOS post-culture were sex, injection drug use, ICU transfer during 
admission, admission source, infectious disease consult, and discharge disposition.  For 
total LOS, associated variables included age, sex, race, malignancy, ICU transfer during 
admission, site of infection, community acquired infection, and admission source, and 
infection disease consult (Table 5).  The distribution of patients readmitted within 30 
days by covariates is depicted in Table 6.  Variables associated with 30-day readmission 
with a p-value ≤ 0.25 included, the Charlson Comorbidity Index, and admission in the 
previous 90 days. 
 The distribution of outcomes by treatment group is described in Table 7.  Briefly, 
patients who received penicillin had a mean duration of bacteremia of 4.7 days, median 
LOS post-culture of 8 days, and median total LOS for patients receiving penicillin was 14 
days.  For patients receiving a different antibiotic or penicillin late, the mean duration of 
bacteremia was 4.6 days, median LOS post-culture was 9 days, and median total LOS 
was 14 days.  Four (50%) patients were readmitted within 30 days in the penicillin group, 
and 11 (18%) were readmitted among patients not receiving or receiving penicillin late 
(Table 8).  All differences in outcomes between the treatment groups were non-
significant.  To further analyze differences in LOS, Kaplan-Meier plots were constructed 
for both total LOS (Figure 4) and LOS after culture (Figure 5).  As depicted in the 
figures, the survival curves for both total LOS and LOS post-culture follow similar 
patterns between the treatment groups. 
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 Unadjusted and adjusted multivariable analyses for the primary outcome of 
duration of bacteremia are shown in Table 9.  As described previously, because of our 
methods of defining treatment exposure, patients with duration of bacteremia of less than 
3 days were excluded, leaving 79 patients available for the analysis.  Duration of 
bacteremia was log-transformed; therefore, the beta coefficients can be interpreted as a 
percent change in the dependent variable for a categorical change in the independent 
variable.  Fifteen (19%) received penicillin within 3 days, and 64 (81%) did not, or 
received penicillin after 3 days.  In the unadjusted analysis, patients in the no/late 
penicillin treatment group exhibited a non-significant 2% decrease in duration of 
bacteremia compared to those in the penicillin group (β = -0.02; 95% CI, -0.19 – 0.16).  
After adjusting for age, presence of diabetes mellitus, and current chemotherapy, patients 
in the no/late penicillin group exhibited a non-significant 3% increase in duration of 
bacteremia as compared to patients receiving penicillin within 3 days, (β = 0.03; 95% CI, 
-0.15 – 0.20).   
Table 10 shows the results of multivariable analyses for LOS post-positive culture 
as well as total LOS.  After excluding patients who were discharged within 3 days of the 
culture, 75 patients were left for the LOS analyses.  The primary LOS outcome of interest 
is LOS post-culture, because this would be the period of time when a patient’s antibiotics 
would have been switched to penicillin in response to the results of the blood culture.  
Nine patients (12%) received penicillin, and 66 (88%) were in the no/late penicillin 
group.  For the unadjusted analysis, patients who did not receive or received penicillin 
late showed a non-significant 3.1% increase in LOS post-culture as compared to those 
receiving penicillin within 3 days (β = 0.031; 95% CI, -0.46 – 0.52).  After adjusting for 
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injection drug use, site of infection, admission source infectious disease consult, and 
discharge disposition, patients in the no/late penicillin group exhibited a non-significant 
25% increase in LOS after culture as compared to those in the penicillin group.  
However, the increase was not statistically significant (β = 0.25; 95% CI, -0.27 – 0.78).  
Total length of stay was also analyzed; the unadjusted analysis shows that patients in the 
no/late penicillin group had a non-significant 9% increase in total LOS as compared to 
those receiving penicillin (β = 0.09; 95% CI, -0.34 – 0.53).  After adjusting for sex, race, 
community acquired infection, admission source, and infectious disease consult, patients 
in the no/late penicillin group had a non-significant 17% increase in total LOS as 
compared to those in the penicillin group (β = 0.17; 95% CI, -0.23 – 0.58).   
 The results of the multivariable analyses for 30-day readmission are depicted in 
Table 11.  After exclusion of 10 deaths and patients who were discharged within 3 days 
of the positive culture, 69 individuals were available for this analysis.  Eight (12%) of 
whom received penicillin within 3 days of the positive culture, and 61 (88%) did not, or 
received penicillin late.  In the unadjusted analysis, patients in the no/late penicillin group 
had a marginally significant reduction in the risk of readmission within 30 days as 
compared to patients in the penicillin group (OR = 0.22; 95% CI, 0.05 – 1.01).  After 
adjustment for admission within the previous 90 days,  the reduction in risk was 
statistically significant; patients in the no/late penicillin group had a significant reduction 
in risk of readmission within 30 days as compared to those who received penicillin within 
3 days (aOR = 0.08; 95% CI, 0.01 – 1.63). 
Propensity score adjusted analyses resulted in no significant differences in clinical 
outcomes between the treatment groups.  Table 12 shows the propensity score adjusted 
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analysis for duration of bacteremia.  Patients in the no/late penicillin group had a non-
significant 4% decrease in duration of bacteremia as compared to patients in the 
penicillin group, after adjusting for propensity score (β = -0.04; 95% CI, -0.24 – 0.15).  
Table 13 depicts results of propensity score adjusted analyses for LOS post-culture and 
total LOS.  Patients not receiving or receiving penicillin late had a non-significant 4% 
decrease in LOS post-culture (β = -0.04; 95% CI, -0.60 – 0.52) as compared to patients 
receiving penicillin after adjusting for propensity score; there was virtually no difference 
in total LOS (β = 0.003; 95% CI, -0.49 – 0.50).  For the analysis of 30-day readmission, 
adjustment for propensity score resulted in an attenuation of the association between 
penicillin treatment and 30-day readmission (Table 14).  Receiving another antibiotic or 
penicillin late was associated with a non-significant 75% decrease in the risk of 
readmission within 30 days as compared to patients receiving penicillin within 3 days 
while adjusting for propensity score (OR = 0.25; 95% CI, 0.04 – 1.59). 
Sensitivity analyses were conducted by redefining our exposure variable as 
receiving penicillin within 4 days of the first positive culture.  In these analyses, patients 
who were discharged, or whose duration of bacteremia was less than 4 hours were 
excluded.  Table 15 shows the results of the sensitivity analysis for duration of 
bacteremia; the results were similar to our primary analysis.  Sensitivity analyses for LOS 
post-culture and total LOS yielded similar results (Table 16).  The results of our 
sensitivity analysis for 30-day readmission were also similar to the primary analysis 
(Table 17). 
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CHAPTER 4 
DISCUSSION 
 
 In this study of 108 patients admitted at Baystate Medical Center with a 
confirmed diagnosis of PSSA bacteremia, our results suggest that there are no large 
differences in clinical outcomes in patients who were treated appropriately with penicillin 
within an appropriate time window, and patients who were treated with a different 
antibiotic or received penicillin more than 3 days after the first positive culture.  After 
performing separate analyses adjusting for patient characteristics and propensity score, 
we observed that duration of bacteremia, and LOS post-culture for both groups were 
similar and non-significant.  The propensity-score-adjusted odds ratio for risk of 30-day 
readmission suggested that patients who received another antibiotic or penicillin late, 
may have had a decreased risk of readmission; however, these results were also 
statistically non-significant. 
 There has only been one other study that has evaluated the effectiveness of 
penicillin versus other antibiotics for the treatment of PSSA bacteremia.
11
 Nissen et al. 
conducted a retrospective cohort study in Denmark, reviewing charts of 588 PSSA 
bacteremia cases in five centers from January 1995 to December 2010.  The primary 
outcome in this study was 30-day mortality rate.  The authors observed that therapy with 
cefuroxime was associated with an increased risk in 30-day mortality as compared to 
treatment with penicillin (HR = 2.54; 95% CI, 1.49 – 4.32).  No significant difference in 
risk of 30-day mortality was observed between patients treated with penicillin and those 
treated with dicloxacillin. 
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Two studies within the past 10 years have explored duration of bacteremia as an 
outcome, although it was not considered the primary outcome for either study.
14, 24
 In 
2011, Lemonovich et al. conducted a retrospective cohort study to examine the 
association between combination therapy with an aminoglycoside for S. aureus 
endocarditis or bacteremia and risk of recurrent bacteremia.
14
 The primary outcome was 
recurrent bacteremia; duration of bacteremia in days was considered as a secondary 
outcome.  The investigators observed that for subjects receiving combination therapy 
with an aminoglycoside, the risk of recurrent bacteremia was significantly lower than 
those who did not receive an aminoglycoside (OR = 0.26; 95% CI, 0.07 – 0.98).  
However, there was no significant difference in the median days of duration of 
bacteremia (p = 0.49).  In 2006, Fowler et al. conducted a randomized controlled trial 
evaluating treatment of S. aureus bacteremia and endocarditis with daptomycin versus 
standard therapy.
24
 In the secondary analyses for duration of bacteremia, the investigators 
observed that for both methicillin-resistant and methicillin-susceptible S. aureus, the 
median duration of bacteremia did not differ significantly between the treatment groups 
(p = 0.25 and 0.28, respectively). 
 Generally, the results of our primary analysis of duration of bacteremia were 
similar to the results of the two more recent studies that considered this as an outcome.  
As with these two studies, the results or our multivariable and propensity-score-adjusted 
analyses suggested that there was no difference in duration of bacteremia between the 
two treatment groups.  However, neither of these previous studies focused on penicillin-
susceptible S. aureus, nor were they evaluating penicillin as a treatment.  Nissen et al. 
conducted the only study evaluating the effectiveness of penicillin in patients with 
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confirmed PSSA bacteremia, but the only outcome investigated was 30-day mortality.  
Thus, the results of this study may not be directly comparable with our study.  It does 
suggest, however, that for PSSA bacteremia, penicillin or other penicillin-class 
antibiotics (such as dicloxacillin) are associated with improved clinical outcomes.  The 
results of our multivariable and propensity-score-adjusted analyses for LOS also 
suggested that there were no significant differences between treatment groups.  The only 
statistically significant association observed was with risk of 30-day readmission.  In our 
multivariable analysis, we found that patients who did not receive, or received penicillin 
late were significantly less likely to be readmitted within 30-days as compared to patients 
treated with penicillin within 3 days post-culture.  However, there were only 69 patients 
available for this analysis, and furthermore, there were very few patients who received 
penicillin and were readmitted in this analysis.  Consequently, the validity of this result 
may be questionable.  Propensity-score-adjusted analysis of 30-day readmission resulted 
in a non-significant decreased risk of 30-day readmission, 
 This study has several limitations that should be addressed.  A substantial 
limitation of this study is the small sample size; particularly after patients with duration 
of bacteremia less than 3 days and patients who were discharged within 3 days of the 
positive culture were excluded.  Furthermore, there were a small number of patients 
included in the penicillin group.  This could have precluded us from detecting any 
differences between treatment groups due to inadequate power.  Also, antibiotics given in 
place of penicillin in the no or late penicillin group were not classified.  Patients not 
receiving penicillin were likely prescribed an antibiotic that was also effective against 
PSSA.  Consequently, these patients may have fared just as well as those who received 
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penicillin in the appropriate time frame, thereby biasing our results towards the null.  This 
could be a plausible explanation for why patients who were treated with penicillin versus 
those treated with other antibiotics exhibited no difference in duration of bacteremia. 
 As with any study evaluating a treatment, confounding by indication is a potential 
for bias in this study.  Physicians may be more likely to treat a patient with a particular 
antibiotic if they present with certain diagnoses or comorbidities.  To minimize the 
impact of this bias, propensity scores were estimated.  The propensity score is a 
conditional probability of a patient receiving a particular treatment, given patient 
characteristics.
23
 Fitness of the propensity score model as assessed with the Hosmer-
Lemeshow goodness of fit test and area under the ROC curve indicated that the model 
was adequate, and was able to mitigate the effects of confounding by indication.  The 
propensity score was then used as a covariate in a multivariable analysis; the results of 
these analyses were similar to our primary analysis. 
 Since we defined the primary exposure as treatment with penicillin within 3 days 
of the first positive culture, there was a potential for immortal time bias.  Immortal time 
bias can occur when there are outcomes during a period of time before an individual is 
considered to be exposed.  This would create a disproportionate number of unexposed 
individuals who experienced an outcome, thereby introducing a systematic bias that 
would underestimate the association.
25
 In the context of our study, to minimize the 
impact of immortal time bias, patients whose bacteremia resolved, or were discharged 
within 3 days after the first positive culture were excluded from the multivariable 
analyses.  If these patients were not excluded, there would be patients who experienced 
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outcomes before there was an opportunity to be treated with penicillin, which would have 
biased our results away from the null. 
 To the best of our knowledge this is the first study to consider duration of 
bacteremia, LOS, and 30-day readmission as outcomes in evaluating treatment with 
penicillin for treatment of PSSA bacteremia.  Although this study was limited by a small 
sample size and lack of statistical power, steps were taken to minimize the impact of 
potential biases.  Furthermore, this patient population represents 10 years of admissions 
at Baystate Medical Center, and exclusion criteria were decided on in order to ensure a 
patient population consisting of unique patients with confirmed cases of PSSA 
bacteremia.  
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CHAPTER 5 
CONCLUSION 
 
 In conclusion, the results of this study suggest that there is no association between 
treatment with penicillin and clinical outcomes.  Given the low cost and decreased risk of 
developing multidrug-resistant bacteria, PSSA bacteremia should be treated preferentially 
with penicillin.  However, given the small sample size, and the potentially wide range of 
antibiotics that may be used in place of penicillin, caution should be exercised in 
interpreting these results.  Directions for further research should include larger multi-site 
studies to address these associations. 
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All (n=108)
Penicillin                   
[n=16 (15%)]
No/Late Penicillin 
[n=92 (85%)]
p -value †
Age, years; [ (SD)] 64 (16.2) 63 (16.9) 64 (16.2) 0.96
Sex 0.42
          Male 64 (59%) 8 (50%) 56 (61%)
Race 0.76
          White 88 (81%) 14 (88%) 74 (80%)
          Black 14 (13%) 1 (6%) 13 (14%)
          Other 6 (6%) 1 (6%) 5 (5%)
Charlson Comorbidity Index 0.98
          0-2 28 (26%) 4 (25%) 24 (26%)
          ≥ 3 80 (74%) 12 (75%) 68 (74%)
Diabetes Mellitus 0.25
          Yes 33 (31%) 7 (44%) 26 (28%)
Malignancy 0.36
          Yes 11 (10%) 0 (0%) 11 (12%)
Chemotherapy 1.00
          Yes 5 (5%) 0 (0%) 5 (5%)
Requirement for Dialysis 0.29
          Yes 20 (19%) 1 (6%) 19 (20%)
Injection Drug Use 0.16
          Yes 5 (5%) 2 (13%) 3 (3%)
Surgical Wound 0.46
          Yes 17 (16%) 1 (6%) 16 (17%)
Indwelling Catheter 0.28
          Yes 46 (43%) 9 (56%) 37 (40%)
ICU during Hospitalization 0.23
          Yes 31 (28%) 7 (43%) 24 (26%)
Site of Infection 0.09
          Catheter Related 13 (12%) 0 (0%) 13 (14%)
          Respiratory 8 (7%) 0 (0%) 8 (9%)
          Endocarditis 9 (8%) 4 (25%) 5 (5%)
          Osteomyelitis 10 (9%) 2 (13%) 8 (9%)
          Dialysis Access 7 (6%) 0 (0%) 7 (8%)
          Other 20 (19%) 4 (25%) 16 (17%)
          Unknown 41 (38%) 6 (38%) 35 (38%)
Community Acquired Infection
          Yes 36 (33%) 5 (31%) 31 (34%) 1.00
Admission in Previous 90 Days 1.00
          Yes 28 (26%) 4 (25%) 24 (26%)
Admission Source 0.51
          Home 66 (61%) 9 (56%) 57 (62%)
          Transfer from SNF 13 (12%) 4 (25%) 9 (10%)
          Emergency Department 14 (13%) 2 (13%) 12 (13%)
          MD/Ref 9 (8%) 1 (6%) 8 (9%)
          Other 6 (6%) 0 (0%) 6 (7%)
Infectious Disease Consult 0.08
          Yes 73 (68%) 14 (88%) 59 (64%)
Discharge Dispostion 0.09
          Longterm Care 35 (32%) 4 (25%) 31 (33%)
          Death 10 (9%) 2 (13%) 8 (9%)
          Home 45 (42%) 4 (25%) 41 (45%)
          Acute/Short-term Care 14 (13%) 5 (31%) 9 (10%)
          Other 4 (4%) 1 (6%) 3 (3%)
Patient Treatment Group
† Significance testing perfomed using independent t-test for continuous variables, 
Wilcoxon's Rank-Sum for ordinal variables, and Fisher's Exact test for categorical variables
Table 1. Characteristics of Study Population by Treatment Group: PSSA at Baystate Medical 
Center, 2003-2013
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 (SD) Median Min 25th% 75th% Max
Duration of bacteremia, days* (n=79)† 4.6 (1.5) 4 3 3 6 9
Total length of stay, days (n=75)‡ 18.1 (13.2) 14 4 10 23 71
Length of stay before positive culture, days (n=75) 6.7 (8.3) 4 0 2 8 56
Length of stay post-positive culture, days (n=75) 11.4 (9.0) 9 3 5 15 49
Table 2.  Distribution of Duration of Bacteremia, Total Length of Stay, and Length of Stay Post-Positive Culture: 
PSSA at Baystate Medical Center, 2003-2013
* Duration of bacteremia defined as time from first positive culture to time of first negative culture
† Excluded patients if duration of bacteremia less than 3 days
‡ Excluded patients if LOS post-culture less than 3 days
N=69* N (%)
30-day Readmission
          No 54 (78%)
          Yes 15 (22%)
Table 3.  Distribution of 30-day Readmisson: PSSA at 
Baystate Medical Center, 2003-2013
* Excluded 10 deaths and if LOS post-culture less than 
3 days
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n=79*  (SD) Median 25th % 75th % p -value†
Age, years (Spearman's rho) ρ = -0.199 --- --- --- 0.08
Sex 0.31
          Male 4.7 (1.5) 4 4 6
          Female 4.3 (1.5) 4 3 5
Race 0.88
          White 4.5 (1.5) 4 3 6
          Black 4.9 (1.7) 4 4 6
          Other 4.8 (1.6) 4 4 6
Charlson Comorbidity Index 0.46
          0-2 4.7 (1.3) 4 4 6
          ≥ 3 4.5 (1.5) 4 3 6
Diabetes Mellitus 0.09
          Yes 5.0 (1.7) 4.5 3.5 6
          No 4.4 (1.3) 4 3 5
Malignancy 0.33
          Yes 4.1 (1.2) 4 3 5
          No 4.6 (1.5) 4 3 6
Chemotherapy 0.06
          Yes 3.0 (0.0) 3 3 3
          No 4.6 (1.5) 4 3 6
Requirement for Dialysis 0.72
          Yes 4.7 (1.4) 4.5 3.5 6
          No 4.6 (1.5) 4 3 6
Injection Drug Use 0.38
          Yes 4.0 (1.2) 4 3 4
          No 4.6 (1.5) 4 3 6
Surgical Wound 0.55
          Yes 4.3 (1.2) 4 3.5 5
          No 4.6 (1.5) 4 3 6
Indwelling Catheter 0.29
          Yes 4.4 (1.5) 4 3 5
          No 4.7 (1.5) 4.5 3 6
ICU during Hospitalization 0.66
          Yes 4.5 (1.5) 4 3 5.5
          No 4.6 (1.5) 4 3 6
Site of Infection 0.81
          Catheter Related 4.4 (1.1) 3 5 5
          Respiratory 4.2 (0.8) 4 4 5
          Endocarditis 4.2 (1.2) 4 3 5
          Osteomyelitis 5.1 (2.3) 4 3 7
          Dialysis Access 4.4 (1.7) 4 3 5
          Other 4.9 (1.4) 4.5 4 6
          Unknown 4.5 (1.5) 4 3 6
Community Acquired Infection 0.50
          Yes 4.7 (1.3) 5 4 6
          No 4.5 (1.6) 4 3 6
Admission in Previous 90 Days 0.78
          Yes 4.7 (1.4) 4.5 3.5 5.5
          No 4.5 (1.5) 4 3 6
Admission Source 0.60
          Home 4.7 (1.5) 4 4 6
          Transfer from SNF 4.1 (1.9) 3 3 5
          Emergency Department 4.4 (1.3) 4.5 3 5.5
          MD/Ref 4.2 (0.9) 4.5 3 5
          Other 5.2 (1.5) 5.5 4 6
Infectious Disease Consult 0.90
          Yes 4.6 (1.6) 4 3 6
          No 4.6 (1.3) 5 3 5
Discharge Dispostion 0.60
          Longterm Care 4.3 (1.4) 4 3 6
          Death 4.6 (1.4) 4.5 3.5 5.5
          Home 4.7 (1.5) 5 3 6
          Acute/Short-term Care 5.0 (1.9) 4 3 7
          Other 3.6 (0.6) 4 3 4
Duration of Bacteremia (days)
Table 4.  Distribution of Duration of Bacteremia by Covariates: PSSA at Baystate Medical 
Center, 2003-2013
† Significance testing perfomed using Spearman's Rank Correlation for continuous and ordinal 
variables and ANOVA for categorical variables.
* Excluded patients if duration of bacteremia less than 3 days
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N=75*  (SD) Median 25th % 75th % p -value†  (SD) Median 25th % 75th % p -value†
Age, years (Spearman's rho) ρ = -0.065 --- --- --- 0.58 ρ = -0.136 --- --- --- 0.24
Sex 0.18 0.18
          Male 12.9 (10.6) 10 5 15 20.3 (15.6) 14 10 23
          Female 9.4 (6.0) 7 5 10 15.2 (8.7) 14 8 20
Race 0.34 0.13
          White 12.1 (9.5) 9.5 6 15 19.4 (14.1) 14.5 10 25
          Black 8.6 (4.6) 7 5 12 13.2 (6.3) 12 8 18
          Other 8.5 (8.2) 5 4 8 11.8 (8.4) 9.5 8 12
Charlson Comorbidity Index 0.97 0.71
          0-2 11.7 (9.1) 8.5 4 15.5 18.4 (12.6) 16 9 22.5
          ≥ 3 11.3 (9.1) 9 5 15 17.9 (13.6) 13 10 23
Diabetes Mellitus 0.29 0.43
          Yes 9.2 (5.5) 7.5 4.5 13 15.3 (8.7) 13.5 9.5 19
          No 12.4 (10.2) 9 6 15 19.4 (14.8) 14 10 24
Malignancy 0.41 0.07
          Yes 12.2 (7.1) 11.5 7 19 21.8 (10.4) 20 17 28
          No 11.2 (9.3) 8 5 15 17.5 (13.6) 13 10 21
Chemotherapy 0.95 0.26
          Yes 10.0 (6.4) 8.5 5.5 14.5 22.3 (9.9) 25.5 15.5 29
          No 11.5 (9.1) 9 5 15 17.8 (13.4) 14 10 21
Requirement for Dialysis 0.69 0.46
          Yes 13.5 (12.5) 10 4 16 21.0 (16.4) 15.5 10 28
          No 10.9 (8.1) 8 5 15 17.4 (12.5) 14 9 22
Injection Drug Use 0.18 0.46
          Yes 18.0 (14.3) 12.5 9 27 25.0 (22.8) 15.5 12.5 37.5
          No 11.0 (8.6) 8 5 15 17.7 (12.6) 14 9 23
Surgical Wound 0.84 0.79
          Yes 10.6 (7.7) 8.5 5 15 18.9 (17.0) 13 9 22
          No 11.6 (9.4) 9 5 15 17.9 (12.4) 14 10 23
Indwelling Catheter 0.85 0.93
          Yes 11.8 (10.7) 8 4 15 19.4 (15.9) 13 9 24
          No 11.1 (7.8) 9 5 15 17.1 (11.1) 14 10 21
ICU during Hospitalization 0.24 0.13
          Yes 11.7 (6.4) 10 7 17.5 20.5 (14.5) 16 11 23.5
          No 11.3 (10.1) 8 5 13 16.9 (12.5) 13 9 21
Site of Infection 0.08 0.24
          Catheter Related 8.4 (6.6) 6 4 12 14.7 (9.5) 12 7 20
          Respiratory 17.4 (6.3) 19 17 20 25.2 (10.2) 23 23 24
          Endocarditis 19.2 (17.6) 10 10 21 26.8 (21.1) 16 14 28
          Osteomyelitis 15.7 (11.6) 12 8 21 20.2 (17.9) 15 11 21
          Dialysis Access 9.4 (4.3) 10 9 10 14.8 (7.5) 13 10 13
          Other 10.5 (10.9) 7 4 13 15.2 (11.3) 10 9 17
          Unknown 9.8 (5.6) 8 5 15 18.1 (13.8) 14 9 26
Community Acquired Infection 0.32 <0.001
          Yes 11.5 (7.9) 9.5 7 15 13.1 (8.1) 10.5 8 15
          No 11.3 (9.9) 8 4 15 22.2 (15.2) 17 11 28
Admission in Previous 90 Days 0.33 0.28
          Yes 12.8 (10.5) 9.5 7 15 19.4 (13.0) 14 12 27
          No 10.8 (8.4) 8 5 15 17.5 (13.4) 14 9 22
Admission Source 0.12 0.12
          Home 10.0 (8.7) 7 5 12 15.4 (10.9) 11 9 17
          Transfer from SNF 11.2 (5.2) 10 8 15 22.0 (18.4) 15 13 28
          Emergency Department 10.7 (7.9) 8 4 19 17.0 (11.7) 13 8 24
          MD/Ref 17.7 (15.6) 12 6 24 28.1 (19.4) 27 12 42
          Other 15.3 (5.9) 15 13 17 20.2 (7.7) 20 17 28
Infectious Disease Consult 0.04 0.02
          Yes 10.2 (8.5) 8 5 12 15.4 (10.4) 12.5 9 17
          No 13.7 (9.7) 12 7 15 23.3 (16.7) 18 12 28
Discharge Dispostion 0.23 0.49
          Longterm Care 12.6 (11.4) 8 5 15 18.9 (13.5) 14 10 22
          Death 12.3 (7.8) 9 7 20 21 (12.7) 18.5 10 28
          Home 9.5 (7.9) 7 4 11 15.6 (11.4) 13 8 17.5
          Acute/Short-term Care 13.6 (6.9) 13.5 9 15 22.7 (18.9) 15.5 12 23
          Other 12.0 (5.7) 12 8 16 14.5 (3.5) 14.5 12 17
† Significance testing performed using Spearman's Rank Correlation for continuous and ordinal variables,  and Kruskal-Wallis for 
categorical variables.
Table 5.  Distribution of Total Length of Stay and Length of Stay Post-Positive Culture by Covariates: PSSA at Baystate Medical Center, 2003-
2013
Length of Stay Post-Positive Culture(days) Total Length of Stay (days)
* Excluded patients if LOS post-culture less than 3 days
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N=69* Yes [n=15 (22%)] No [n=54 (78%)] p -value †
Age, years; [ (SD)] 64 (17.4) 60 (15.7) 0.44
Sex 0.77
          Male 8 (53%) 32 (59%)
Race 0.57
          White 11 (73%) 44 (81%)
          Black 2 (13%) 7 (13%)
          Other 2 (13%) 3 (6%)
Charlson Comorbidity Index 0.17
          0-2 2 (13%) 17 (31%)
          ≥ 3 13 (87%) 37 (69%)
Diabetes Mellitus 0.36
          Yes 7 (47%) 17 (31%)
Malignancy 0.36
          Yes 3 (20%) 5 (9%)
Chemotherapy 1.00
          Yes 0 (0%) 3 (6%)
Requirement for Dialysis 0.72
          Yes 2 (13%) 11 (20%)
Injection Drug Use 0.53
          Yes 1 (7%) 2 (4%)
Surgical Wound 0.46
          Yes 4 (27%) 9 (17%)
Indwelling Catheter 0.77
          Yes 7 (47%) 22 (41%)
ICU during Hospitalization 1.00
          Yes 4 (27%) 16 (30%)
Site of Infection 0.99
          Catheter Related 3 (20%) 8 (15%)
          Respiratory 0 (0%) 3 (6%)
          Endocarditis 1 (7%) 3 (6%)
          Osteomyelitis 1 (7%) 6 (11%)
          Dialysis Access 1 (7%) 4 (7%)
          Other 4 (27%) 11 (20%)
          Unknown 5 (33%) 19 (35%)
Community Acquired Infection 1.00
          Yes 5 (33%) 28 (34%)
Admission in Previous 90 Days < 0.001
          Yes 11 (73%) 11 (20%)
Admission Source 0.64
          Home/Self-Referred 7 (47%) 33 (61%)
          Transfer from SNF 2 (13%) 7 (13%)
          Emergency Department 3 (20%) 5 (9%)
          MD/Ref 2 (13%) 4 (7%)
          Other 1 (7%) 5 (9%)
Infectious Disease Consult 0.75
          Yes 11 (73%) 36 (67%)
Discharge Dispostion 0.38
          Longterm Care 6 (40%) 19 (35%)
          Home 5 (33%) 27 (50%)
          Acute/Short-term Care 3 (20%) 7 (13%)
          Other 1 (7%) 1 (2%)
30-day Readmission
Table 6.  Distribution of 30-day Readmission by Covariates: PSSA at Baystate 
Medical Center, 2003-2013
* Excluded 10 deaths and if LOS post-culture less than 3 days
† Significance testing perfomed using independent t-test for continuous variables, 
Wilcoxon's Rank-Sum for ordinal variables, and Fisher's Exact test for categorical 
variables
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N=69*
Penicillin 
[n=8 (12%)]
No/Late Penicillin 
[n=61 (88%)]
p -value†
30-day Readmission, N (%) 0.06
          No 4 (50%) 50 (82%)
          Yes 4 (50%) 11 (18%)
Table 8. Distribution of 30-day Readmisson by Antibiotic Treatment: PSSA 
at Baystate Medical Center, 2003-2013
† Significance testing performed using Fisher's exact test
* Excluded 10 deaths and if LOS post-culture less than 3 days
N=79* N(%) Beta (SE) 95% CI p- value Beta (SE) 95% CI p- value
Antibiotic Treatment
          Penicillin 15 (19%) Referent Referent
          No/Late Penicillin 64 (81%) -0.02 (0.09) -0.19 , 0.16 0.86 0.03 (0.08) -0.15 , 0.20 0.77
* Excluded subjects if duration of bacteremia was less than 3 days
Table 9. Unadjusted and Adjusted Multivariable Analysis of Log-Transformed Duration of Bacteremia: PSSA at 
Baystate Medical Center, 2003-2013
Unadjusted Adjusted†
------ ------
Duration of Bacteremia
† Adjusted for age, diabetes mellitus and current chemotherapy
 30 
 
 
N
(%
)
Be
ta
 (S
E)
95
%
 C
I
p-
va
lu
e
Be
ta
 (S
E)
95
%
 C
I
p-
va
lu
e
N
(%
)
Be
ta
 (S
E)
95
%
 C
I
p-
va
lu
e
Be
ta
 (S
E)
95
%
 C
I
p-
va
lu
e
A
nt
ib
io
ti
c 
Tr
ea
tm
en
t
   
   
   
 P
en
ic
ill
in
9 
(1
2%
)
Re
fe
re
nt
Re
fe
re
nt
9 
(1
2%
)
Re
fe
re
nt
Re
fe
re
nt
   
   
   
 N
o/
La
te
 P
en
ic
ill
in
66
 (8
8%
)
0.
03
1 
(0
.2
4)
-0
.4
6 
, 0
.5
2
0.
90
0.
25
 (0
.2
6)
-0
.2
7 
, 0
.7
8
0.
34
66
 (8
8%
)
0.
09
 (0
.2
2)
-0
.3
4 
, 0
.5
3
0.
67
0.
17
 (0
.2
0)
-0
.2
3 
, 0
.5
8
0.
40
Ta
bl
e 
10
. U
na
dj
us
te
d 
an
d 
A
dj
us
te
d 
M
ul
ti
va
ri
ab
le
 A
na
ly
si
s 
of
 L
og
-T
ra
ns
fo
rm
ed
 T
ot
al
 L
en
gt
h 
of
 S
ta
y 
an
d 
Le
ng
th
 o
f S
ta
y 
Po
st
-P
os
it
iv
e 
Cu
lt
ur
e:
 P
SS
A
 a
t B
ay
st
at
e 
M
ed
ic
al
 C
en
te
r,
 2
00
3-
20
13
To
ta
l L
en
gt
h 
of
 S
ta
y 
(N
=7
5)
*
Le
ng
th
 o
f S
ta
y 
Po
st
-P
os
it
iv
e 
Cu
lt
ur
e 
(N
=7
5)
*
U
na
dj
us
te
d
A
dj
us
te
d‡
U
na
dj
us
te
d
A
dj
us
te
d†
* 
Ex
cl
ud
ed
 s
ub
je
ct
s 
if
 le
ng
th
 o
f s
ta
y 
po
st
-c
ul
tu
re
 le
ss
 th
an
 3
 d
ay
s
† 
A
dj
us
te
d 
fo
r i
nj
ec
ti
on
 d
ru
g 
us
e,
 s
it
e 
of
 in
fe
ct
io
n,
 a
dm
is
si
on
 s
ou
rc
e,
 ID
 c
on
su
lt
, a
nd
 d
is
ch
ar
ge
 d
is
po
si
ti
on
--
--
-
--
--
-
--
--
-
--
--
-
‡ 
A
dj
us
te
d 
fo
r s
ex
, r
ac
e,
 s
it
e 
of
 in
fe
ct
io
n,
 c
om
m
un
it
y 
aq
ui
re
d 
in
fe
ct
io
n,
 a
dm
is
si
on
 s
ou
rc
e,
 a
nd
 ID
 c
on
su
lt
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N=69* N(%) Crude OR 95% CI p- value aOR 95% CI p- value
Antibiotic Treatment
          Penicillin 8 (12%) 1.00 1.00
          No/Late Penicillin 61 (88%) 0.22 0.05, 1.01 0.05 0.08 0.01, 0.63 0.02
* Excluded 10 deaths and if LOS post-culture less than 3 days
† Adjusted for admission within previous 90 days
Table 11. Unadjusted and Adjusted Multivariable Analysis of 30-day Readmission: PSSA at Baystate Medical 
Center, 2003-2013
Unadjusted Adjusted†
Referent Referent
N=79† N(%) Beta (SE) 95% CI p- value
Antibiotic Treatment
          Penicillin 15 (19%) Referent
          No/Late Penicillin 64 (81%) -0.04 (0.10) -0.24 , 0.15 0.67
Table 12. Propensity Score Adjusted Analysis of Log-Transformed Duration 
of Bacteremia: PSSA at Baystate Medical Center, 2003-2013*
--
Duration of Bacteremia
* Variables included in propensity score estimator: admission in previous 
90 days, year of admission, ICU during admission, sex, race, age, injection 
drug use, presence of surgical wound, indwelling catheter, dialysis 
requirement, id consult, diabetes mellitus, and CCI
† Excluded subjects if duration of bacteremia was less than 3 days
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N(%) Beta (SE) 95% CI p- value N(%) Beta (SE) 95% CI p- value
Antibiotic Treatment
          Penicillin 9 (12%) Referent 9 (12%) Referent
          No/Late Penicillin 66 (88%) -0.04 (0.28) -0.60 , 0.52 0.93 66 (88%) 0.003 (0.24) -0.49 , 0.50 0.98
† Excluded subjects if length of stay post-culture less than 3 days
Table 13. Propensity Score Adjusted  Analysis of Log-Transformed Total Length of Stay and Length of Stay Post-Positive Culture: 
PSSA at Baystate Medical Center, 2003-2013*
----- -----
Total Length of Stay, days  (N=75)†
* Variables included in propensity score estimator: admission in previous 90 days, year of admission, ICU during admission, sex, 
race, age, injection drug use, presence of surgical wound, indwelling catheter, dialysis requirement, id consult, diabetes mellitus, 
Length of Stay Post-Positive Culture, days (N=75)†
N=69† N(%) OR 95% CI p- value
Antibiotic Treatment
          Penicillin 8 (12%) 1.00
          No/Late Penicillin 61 (88%) 0.25 0.04 , 1.59 0.14
Table 14. Propensity Score Adjusted Analysis of 30-day Readmission: 
PSSA at Baystate Medical Center, 2003-2013*
Referent
* Variables included in propensity score estimator: admission in 
previous 90 days, year of admission, ICU during admission, sex, race, 
age, injection drug use, presence of surgical wound, indwelling 
catheter, dialysis requirement, id consult, diabetes mellitus, and CCI
† Excluded 10 deaths and if LOS post-culture less than 3 days
N=55* N(%) Beta (SE) 95% CI p- value
Antibiotic Treatment
          Penicillin 19 (34%) Referent
          No/Late Penicillin 36 (65%) 0.09 (0.08) -0.06 , 0.25 0.22
* Excluded subjects if duration of bacteremia was less than 4 days
† Adjusted for sex, chemotherapy, and admission source
Duration of Bacteremia
‡ Exposure defined as penicillin treatment within 4 days
Table 15. Sensitivity Analysis of Log-Transformed Duration of 
Bacteremia: PSSA at Baystate Medical Center, 2003-2013‡
Adjusted†
------
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N(%) Beta (SE) 95% CI p- value N(%) Beta (SE) 95% CI p- value
Antibiotic Treatment
          Penicillin 16 (23%) Referent 16 (23%) Referent
          No/Late Penicillin 53 (77%) 0.36 (0.24) -013 , 0.85 0.14 53 (77%) 0.22 (0.21) -0.18 , 0.64 0.27
Table 16. Sensitivity Analysis of Log-Transformed Total Length of Stay and Length of Stay Post-Positive Culture: PSSA at 
Baystate Medical Center, 2003-2013*
Adjusted†
* Exposure defined as penicillin treatment within 4 days
‡ Adjusted for age, injection drug use, icu during hospitalization, community acquired infection, previous 
admission within 90 days, admission source, and ID consult
† Adjusted for race, icu during admission, community aquired infection, and admission source
** Excluded subjects if length of stay post-culture less than 4 days
Total LOS, days (N=69)**LOS Post-Positive Culture, days (N=69)**
Adjusted‡
----------
N=63* N(%) aOR 95% CI p- value
Antibiotic Treatment
          Penicillin 15 (23%) 1.00
          No/Late Penicillin 48 (76%) 0.09 0.01 , 0.71 0.02
* Excluded 10 deaths and if LOS post-culture less than 4 days
‡ Exposure defined as penicillin treatment within 4 days
Table 17. Sensitivity Analysis of 30-day Readmission: PSSA at Baystate 
Medical Center, 2003-2013‡
Adjusted†
Referent
† Adjusted for admission within previous 90 days
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Figure 1. Exclusion Criteria; PSSA at Baystate Medical Center, 2003-2013
 35 
 
 
 
 
 
 
Figure 2.  Histogram of Duration of Bacteremia; PSSA at Baystate Medical Center, 2003-2013
Figure 3.  Histogram of Total Length of Stay; PSSA at Baystate Medical Center, 2003-2013
N = 79 
N = 75 
 36 
 
 
 
 
 
 
Figure 4.  Kaplan-Meier Plot for Total Length of Stay; PSSA at Baystate Medical Center, 2003-2013
Figure 5.  Histogram of Length of Stay After Positive Culture; PSSA at Baystate Medical 
Center, 2003-2013
N = 75 
N = 75 
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Figure 6.  Kaplan-Meier Plot for Length of Stay After Positive Culture; PSSA at Baystate Medical Center, 
2003-2013
N = 75 
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